• 1
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993; 329: 977 86.
  • 2
    Reichard P, Nilsson BY, Rosenqvist U. The effect of long term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304 9.
  • 3
    Howard-Williams J, Hillson RM, Bron A, Awdry P, Mann JI, Hockaday TDR. Retinopathy is associated with higher glycaemia in maturity-onset type diabetes. Diabetologia 1984; 27: 198 202.
  • 4
    Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 1988; 260: 2864 71.
  • 5
    Klein R, Klein BEK, Moss SE, Cruickshanks KJ. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 1994; 154: 2169 78.
  • 6
    Landin-Olsson M, Nilsson KO, Lernmark Å, Sundkvist G. Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabetologia 1990; 33: 561 8.
  • 7
    Mølbak AG, Christau B, Marner B, Borch-Johnsen K, Nerup J. Incidence of insulin-dependent diabetes mellitus in age groups over 30 years in Denmark. Diabetic Med 1994; 11: 650 5.
  • 8
    Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark Å, Sundkvist G. β-cell function in relation to islet-cell antibodies (ICA) during the first three years after clinical diagnosis of diabetes in non-insulin-dependent (type II) diabetic patients. Diabetes Care 1993; 16: 902 10.
  • 9
    Gottsäter A, Landin-Olsson M, Lernmark Å, Fernlund P, Sundkvist G. Islet cell antibodies are associated with β-cell failure also in obese adult onset diabetic patients. Acta Diabetol 1994; 31: 226 31.
  • 10
    Gottsäter A, Ahmed M, Lilja B, Fernlund P, Sundkvist G. Islet cell antibodies at diagnosis, but not leanness, relate to a better cardiovascular risk profile five years after diagnosis of non-insulin-dependent diabetes mellitus. Diabetes Care 1996; 19: 60 3.
  • 11
    Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989; 107: 237 43.
  • 12
    Moss SE, Meuer SM, Klein R, Hubbard LD, Brothers RJ, Klein BEK. Are seven standard photographic fields necessary for classification of diabetic retinopathy? Invest Ophthalmol Vis Sci 1989; 30: 823 8.
  • 13
    Heding LS. Radioimmunological determination of C-peptide in serum. Diabetologia 1975; 11: 541 8.
  • 14
    Jeppsson JO, Jerntorp P, Sundkvist G, Englund H, Nylund V. Measurement of Hemoglobin A1c by a new Liquid-Chromatographic Assay: Methodology, clinical utility, and relation to glucose tolerance evaluated. Clin Chem 1986; 32: 1867 72.
  • 15
    Burstein M, Scholnik HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitations with polyanions. J Lipid Res 1970; 11: 583 95.
  • 16
    Feldt-Rasmussen B, Mathiesen E, Hegedüs L, Deckert T. Kidney function during 12 months of strict metabolic control in insulin-dependent diabetic patients with incipient nephropathy. N Engl J Med 1986; 314: 665 70.
  • 17
    Bröchner-Mortensen J. A simple method for determination of glomerular filtration rate. Scand J Clin Lab Invest 1972; 30: 271 4.
  • 18
    Sundkvist G, Almér L-O, Lilja B. Respiratory influence on heart rate in diabetes mellitus. Br Med J 1979; 1: 924 5.
  • 19
    Sundkvist G, Lilja B, Almér L-O. Abnormal diastolic blood pressure and heart rate reactions to tilt in diabetes mellitus. Diabetologia 1980; 19: 433 8.
  • 20
    Bergström B, Lilja B, Österlin S, Sundkvist G. Autonomic neuropathy in type 1 diabetes; influence of duration and other diabetic complications. Acta Med Scand 1987; 222: 147 54.
  • 21
    Madsen OD, Landin-Olsson M, Bille G, Sundkvist G, Lernmark Å, Dahlquist G, Ludvigsson J. A two-colour immunofluorescence test with a monoclonal human proinsulin antibody improves the assay for islet cell antibodies. Diabetologia 1986; 29: 115 18.
  • 22
    Landin-Olsson M, Sundkvist G, Lernmark Å. Prolonged incubation on the two-colour immunofluorescent test increases the prevalence and titres of islet cell antibodies in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 327 32.
  • 23
    Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 1992; 15: 815 19.
  • 24
    Henricsson M, Nilsson A, Groop L, Heijl A, Janzon L. Prevalence of diabetic retinopathy in relation to age at onset of the diabetes, treatment, duration and glycaemic control. Acta Ophthalmol Scand 1996; 74: 523 7.
  • 25
    Klein R, Klein BEK, Moss SE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVI. The relationship of C-peptide to the incidence and progression of diabetic retinopathy. Diabetes 1995; 44: 796 801.
  • 26
    Klein R, Klein BEK, Moss SE, Davis MD, De Mets DL. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med 1989; 149: 2427 32.
  • 27
    Teuscher A, Schnell H, Wilson PWF. Incidence of diabetic retinopathy and relationship to baseline plasma glucose and blood pressure. Diabetes Care 1988; 11: 246 51.
  • 28
    Falkenberg M & Finnström K. Associations with retinopathy in type 2 diabetes: a population-based study in a Swedish rural area. Diabetic Med 1994; 11: 843 9.